41.33
1.03 (2.56%)
| Previous Close | 40.30 |
| Open | 40.04 |
| Volume | 1,463,330 |
| Avg. Volume (3M) | 2,688,939 |
| Market Cap | 6,491,745,280 |
| Price / Earnings (TTM) | 275.53 |
| Price / Earnings (Forward) | 27.55 |
| Price / Sales | 18.67 |
| Price / Book | 26.86 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | 7.11% |
| Operating Margin (TTM) | 27.68% |
| Diluted EPS (TTM) | 0.150 |
| Quarterly Revenue Growth (YOY) | 146.00% |
| Quarterly Earnings Growth (YOY) | -96.60% |
| Total Debt/Equity (MRQ) | 114.40% |
| Current Ratio (MRQ) | 6.25 |
| Operating Cash Flow (TTM) | -40.52 M |
| Levered Free Cash Flow (TTM) | -62.02 M |
| Return on Assets (TTM) | 5.78% |
| Return on Equity (TTM) | 12.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | TG Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.38% |
| % Held by Institutions | 62.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Opaleye Management Inc. | 31 Dec 2024 | 2,260,000 |
| 1832 Asset Management L.P. | 31 Dec 2024 | 1,655,100 |
| 52 Weeks Range | ||
| Median | 55.00 (33.08%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2025 | 55.00 (33.08%) | Buy | 35.62 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |